Previous 10 | Next 10 |
2024-03-28 07:20:31 ET More on Can-Fite Biopharma Seeking Alpha’s Quant Rating on Can-Fite Biopharma Historical earnings data for Can-Fite Biopharma Financial information for Can-Fite Biopharma Read the full article on Seeking Alpha For further...
Ewopharma acquired marketing rights for namodenoson in the treatment of pancreatic carcinoma Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseas...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, today announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic a...
Patent has already been issued in other major markets including the U.S., EU, Japan and China Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseas...
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the p...
Piclidenoson is a small molecule safe oral drug suitable for the chronic treatment of patients who suffer from moderate to severe plaque psoriasis. Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary smal...
Robust support for Namodenoson’s potential development as an anti-obesity drug, a projected $100 billion market by 2030 Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address...
FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson’s good safety profile There is an unmet need for safe, convenient, and effective drugs to treat chronic plaque psoriasis in children Can-Fite BioPharma Ltd . (NYSE A...
Study will aim to enroll about 20 patients to establish safety and clinical activity Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, tod...
2023-11-30 07:08:39 ET More on Can-Fite Biopharma Can-Fite climbs on mid-stage data for liver cancer therapy Can-Fite Biopharma discloses $100M mixed shelf offering - filing Seeking Alpha’s Quant Rating on Can-Fite Biopharma Historical earnings data fo...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...